Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)
NCT02566161 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 957
Last updated 2021-03-12
Summary
Data on transgenerational effects following nuclear accidents are important for understanding fully the consequences of parental exposure to ionizing radiation. Few studies to date have had adequate statistical power to detect effects of the magnitude expected based on animal data, and most have not been of low-dose, protracted exposures associated with nuclear accidents and their aftermath. Although, to date, scant use has been made of the new genomic technologies, in Chernobyl-exposed areas of Ukraine and Belarus, excess minisatellite mutations have been seen in children born after the accident. We propose a study of parent-child trios in which at least one parent was exposed to Chernobyl radiation as a clean-up worker (mean dose \>=100 mGy) and/or evacuee from a contaminated area (mean \>= 50mGy). The specific aims are to investigate the transgenerational and de novo mutation rates of the spectrum of genetic variants in trios, in particular looking at effects in children and mapping them to possible parental origin of the chromsome. Together with long-term collaborators at the Research Center for Radiation Medicine (RCRM) in Kiev, epidemiologic data will be collected for up to 450 trios of parents with preconceptional doses and their unexposed offspring. We will use state-of-the-art genomic technologies to characterize the landscape of the genomes of the trios to determine whether parental radiation exposure is associated with genetic mutations transmitted to the offspring, by examining de novo mutation rates, minisatellite mutations, copy number alterations, and variations in telomere length. The analysis will be conducted in peripheral blood and/or buccal samples (when blood is not available) from complete father-mother-child trios. Doses to the gonads from the time of the accident to the time of conception will be reconstructed for all parents using existing records supplemented by interview data.
Trio subjects will be selected from representative populations exposed to radiation from Chernobyl who are under active follow-up in the Clinico-Epidemiologic Registry at RCRM. To help identify specific effects of paternal and maternal radiation exposure, we will initially select sets of trio subjects in five categories: (1) exposed father, unexposed mother; (2) unexposed father, exposed mother; (3) both parents exposed; (4) both parents unexposed; and (5) a group of high dose emergency workers with acute radiation syndrome. All trio members will be invited to the RCRM outpatient clinic for collection of a 20 ml blood sample (or buccal cells for those who refuse phlebotomy). Both parents will be asked to complete a general questionnaire to obtain demographic and lifestyle data. Then one or both will complete detailed dosimetry questionnaires, based on forms used in previous collaborations with RCRM and administered by specially trained interviewers. Once 50 trios have been recruited (10 from each of the 5 exposure categories), we will conduct an interim evaluation of participation rates, sample collection and quality, and dose reconstruction in order to modify the protocol as needed. The analytical approach will be to correlate the extent, especially for de novo events of genetic alterations in the offspring with parental preconceptional radiation dose overall and by parental origin. The statistical power in relation to de novo mutations is very high, in excess of 90%, but somewhat lower for trends in minisatellite mutations. Study findings will contribute importantly to knowledge of the heritable effects of moderate- and low-dose radiation exposure in humans and to radiation risk projection. Eventually data from the Trio Study may be shared with the international community through dbGap.
Conditions
- Genetics
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Amy Berrington, M.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-10-01
- Primary Completion
- 2020-07-10
- Completion
- 2020-07-10
Countries
- Ukraine
Study Locations
More Related Trials
-
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
NCT00949052 ·Status: TERMINATED
-
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
NCT00923026 ·Status: ENROLLING_BY_INVITATION
-
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
NCT04902144 ·Status: COMPLETED ·Phase: NA
-
Optimization of Radiation Protection Through Genomic Analyses
NCT06253338 ·Status: RECRUITING ·Phase: NA
-
Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation
NCT02664389 ·Status: TERMINATED ·Phase: NA
-
New Strategies to Detect Cancers in Carriers of Mutations in RB1
NCT04164134 ·Status: COMPLETED
-
Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries (Primary + Recurrent, or 2 Separate Types of Cancer)
NCT01167842 ·Status: COMPLETED
-
Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia
NCT01653613 ·Status: UNKNOWN
-
Familial Investigations of Childhood Cancer Predisposition
NCT03050268 ·Status: RECRUITING
-
A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women
NCT00858078 ·Status: COMPLETED
-
Pre-existing Kinase Domain Mutations in Ph-positive Leukemias
NCT02643888 ·Status: UNKNOWN
-
Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries
NCT05769517 ·Status: RECRUITING
-
A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention
NCT06436157 ·Status: RECRUITING ·Phase: NA
-
Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples
NCT00001814 ·Status: COMPLETED
-
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
NCT00001163 ·Status: ACTIVE_NOT_RECRUITING
-
Genomic Analysis of Families With a History of Discordant Cancers
NCT04860453 ·Status: RECRUITING
-
Rare Tumors and Cancer Predisposition in Individuals and Families
NCT05350761 ·Status: RECRUITING
-
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
NCT04792463 ·Status: RECRUITING
-
Studying Genes in Samples From Younger Patients With Adrenocortical Tumor
NCT01528956 ·Status: COMPLETED
-
Viral Reactivation and Skin Cancer
NCT02395562 ·Status: COMPLETED
-
Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer
NCT05356585 ·Status: WITHDRAWN
-
Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients
NCT01623856 ·Status: COMPLETED
-
Blood Samples From Healthy Volunteers for Genetic Studies in the East Anglia Region of the United Kingdom
NCT00757991 ·Status: UNKNOWN
-
Pancreatic Cancer Genetics
NCT01102569 ·Status: RECRUITING
-
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer
NCT02470819 ·Status: WITHDRAWN ·Phase: NA